AZN

Announcements

Nothing here yet

Daily updates

• AstraZeneca acquired an approximately 10% stake in Summit Therapeutics in a $2 billion deal to investigate combinations of their cancer therapies.Sep 30, 2026
• FDA began Priority Review of tozorakimab for COPDSep 9, 2026

FDA designations

• ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast CancerJul 21, 2025

News

• AstraZeneca opens a new R&D center in Cambridge, Massachusetts, as part of a $1 billion state investmentOct 6, 2026
• Perioperative IMFINZI plus neoadjuvant enfortumab vedotin receives U.S. Priority Review for patients with muscle-invasive bladder cancerSep 25, 2026
• CHMP recommended EU approval of Enhertu as an adjuvant treatment for patients with residual HER2-positive early breast cancer after neoadjuvant therapySep 18, 2026
• TAGRISSO demonstrated an unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in the Phase 3 ADAURA trialSep 14, 2026
• ENHERTU achieved a 14.3-month median progression-free survival as first-line therapy in HER2-mutant advanced NSCLC in the Phase 3 DESTINY-Lung04 trialSep 14, 2026